Viewing Study NCT01614756


Ignite Creation Date: 2025-12-24 @ 11:29 PM
Ignite Modification Date: 2025-12-25 @ 9:16 PM
Study NCT ID: NCT01614756
Status: COMPLETED
Last Update Posted: 2015-08-19
First Post: 2012-06-06
Is NOT Gene Therapy: False
Has Adverse Events: False

Brief Title: A Two-Part, Phase 1, Single-Dose Study of IL-31 mAb (Anti-Interleukin 31 Monoclonal Antibody); in Healthy Subjects and Adults With Atopic Dermatitis
Sponsor: Bristol-Myers Squibb
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module